Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Daniel Bowles and Elizabeth Kessler.
|
|
Connection Strength |
|
|
|
|
|
0.477 |
|
|
|
-
Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW. Cabozantinib use in renal cell carcinoma. Drugs Today (Barc). 2017 May; 53(5):299-307.
Score: 0.147
-
Kessler ER, Moss A, Eckhardt SG, Laudenslager ML, Kilbourn K, Mauss IB, Bowles DW, Hecker S, Fairclough DL, Kutner JS. Distress among caregivers of phase I trial participants: a cross-sectional study. Support Care Cancer. 2014 Dec; 22(12):3331-40.
Score: 0.122
-
Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44.
Score: 0.107
-
Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov; 47(11):857-68.
Score: 0.100
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|